PharmGKB summary: venlafaxine pathway

Pharmacogenet Genomics. 2014 Jan;24(1):62-72. doi: 10.1097/FPC.0000000000000003.

Authors

Katrin Sangkuhl¹, Julia C Stingl, Miia Turpeinen, Russ B Altman, Teri E Klein

Affiliation

¹ Departments of aGenetics bBioengineering, Stanford University, Stanford, California, USA cInstitute of Pharmacology of Natural Products & Clinical Pharmacology, University of Ulm, Ulm dResearch Division, Federal Institute of Drugs & Medical Devices (BfArM), Bonn, Germany eDepartment of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, Oulu, Finland.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Animals
Aryl Hydrocarbon Hydroxylases / genetics*
Aryl Hydrocarbon Hydroxylases / metabolism
Cyclohexanols / adverse effects
Cyclohexanols / pharmacokinetics*
Cyclohexanols / pharmacology
Cytochrome P-450 CYP2C19
Cytochrome P-450 CYP2D6 / genetics*
Cytochrome P-450 CYP2D6 / metabolism
Depression / drug therapy*
Depression / genetics
Genetic Variation
Genotype
Humans
Metabolic Networks and Pathways / genetics
Mice
Pharmacogenetics
Selective Serotonin Reuptake Inhibitors / adverse effects
Selective Serotonin Reuptake Inhibitors / pharmacokinetics*
Selective Serotonin Reuptake Inhibitors / pharmacology
Substrate Specificity
Venlafaxine Hydrochloride

Substances

Cyclohexanols
Serotonin Uptake Inhibitors
Venlafaxine Hydrochloride
Aryl Hydrocarbon Hydroxylases
CYP2C19 protein, human
Cytochrome P-450 CYP2C19
Cytochrome P-450 CYP2D6

Grants and funding